Celgene Corporation (CELG) is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid (lenalidomide), for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both Thalomid and Revlimid are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene also receives royalties from Novartis Pharma AG on sales of the entire Ritalin family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD). Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.
Reported before open today (4/28/16) Earnings: EPS $1.32 Revenue $2.51B Estimates: EPS $1.26 Revenue $2.58B
It's bounced pretty well off that $95-$96 area quite a few times. Might not be a bad spot to hope for another one with a fairly tight stop.
$CELG may not be as sexy as other bio's, but they are certainly one of the most profitable and stable. Here is the weekly chart: posted by 11ChartsReport on stocktwits.com
https://www.thestreet.com/story/14189774/1/celgene-heading-for-all-time-high.html Since last week's close the IBB, the largest Biotech ETF of the group, has surged more than 6%. Today this index is trading at new 2017 highs with the help of an aggressive buying wave. Celgene Corp. (CELG) , the largest holding in the IBB Index, is leading the charge. The stock is up more than 4% as it drives past heavy resistance near the 2016 spike high. An extended rally into all-time high territory for the multinational biopharmaceutical company is developing. Celgene mounted a monster post-election breakout on Nov. 9. The stock soared more than 10% that session but left behind an ominous spike high in the aftermath. CELG began to fade the next day, eventually retracing the entire post-election surge. The stock remained listless until a powerful breakout in mid February but heavy resistance near the Nov. 9 peak capped the rally. This level, just above $127.00, has proven to be a major roadblock, until today. In late May, CELG built a solid base near its 200-day moving average. As June began the stock was back in rally mode. Last Friday upside volume began to surge as the stock neared the old highs. Today this aggressive accumulation wave continues as the stock blows past the 2016 peak. In the near term investors should consider the stock a low risk buy on weakness. A major support zone is now in place from the $128.00 to $126.00 area. A fade back to this area may not be in the cards anytime soon but the stock will need to consolidate before reaching its all time highs set back in 2015 at $140.70.
Drug That Celgene Bought For $710 Million Fails - https://www.forbes.com/sites/matthe...otix&partner=yahootix&yptr=yahoo#3b716b742377
Many people will not know the financial impact of Celgene stopping two trials for Crohn's disease. Celgene has announced that info in an SEC filing. http://alphastreet.com/bce290d5
Do you run Alphastreet? Feel free to post in here: https://stockaholics.net/forums/vendors-brokers-and-product-reviews.8/
Celgene shares drop 15% on updated 2017 guidance Celgene Corp. CELG, -0.65% shares dropped 15% in premarket trade Thursday after the company reported a third-quarter profit beat and revenue miss and lowered its 2017 profit and revenue outlook. Earnings for the latest quarter rose to $988 million, or $1.21 per share, from $171 million, or $1.21 per share in the year-earlier period. Adjusted earnings-per-share were $1.91, above the FactSet consensus of $1.87. Revenue rose to $3.29 billion from $2.98 billion, below the FactSet consensus of $3.42 billion. Sales of Revlimid, Otezla, Abraxane and Vidaza came in below consensus, while sales of Pomalyst beat the consensus. Celgene also lowered its 2017 revenue and EPS guidance, bringing revenue guidance to about $13 billion, compared with previous guidance of $13 billion to $13.4 billion, and bringing EPS guidance down to $4.78 to $5.19, compared with previous guidance of $5.36 to $5.62. The company's updated 2017 revenue outlook is below the FactSet consensus of $13.23 billion, and its new 2017 EPS guidance is below the FactSet consensus of $5.33. Celgene also increased the lower end of its adjusted EPS guidance, bringing its 2017 EPS outlook to $7.30 to $7.35 from previous guidance of $7.25 to $7.35, compared with the FactSet consensus of $7.32. Celgene shares have dropped 13.2% over the last three months, compared with a 3.2% rise in the S&P 500 SPX, -0.47%
http://alphastreet.com/b0662389 A cut in Celgene's outlook, especially it's long-term targets, is not an encouraging one. Also, a decrease in pharma company's research and development expenses is not a good sign.
Lannett works out a deal with Celgene - https://www.bizjournals.com/philade...ent-thalomid-pharma.html?ana=yahoo&yptr=yahoo
By using BI Analyzing System, the result of this stock as shown in the below: The last arrow is on 2017/Oct./13, and that is a DOWN arrow, which means NOT THE GOOD TIME TO BUY YET. ***“BI Analyzing System” can download from Apple Store / Google Play for free to use.***
I personally won't sell but this going down close to 100 today. Looking forward to that buying opportunity to add more shares
There's a few gaps to fill on this one, depends on how investors feel about the acquisition of JUNO though. Celgene's $9 Billion Buyout of Juno: Is It a Good Deal for Investors? Source: https://www.msn.com/en-us/money/top...no-is-it-a-good-deal-for-investors/ar-AAv2geV Reports generated excitement last week that Celgene (CELG) planned to buy out Juno Therapeutics (JUNO). Neither company commented on the rumors then. But Monday morning, Celgene confirmed that it was indeed acquiring Juno for $9 billion. The deal was obviously a great one for Juno shareholders, who have seen their positions nearly double in value in less than a week. But is the acquisition a good one for Celgene investors? That's a harder question to answer.
